Negative Impact of Blood Transfusion on Recurrence and Prognosis of Hepatocellular Carcinoma After Hepatic Resection

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2009 Jul 8

PMID 19582515

Citations 39

Authors

Hiroaki Shiba

Yuichi Ishida

Shigeki Wakiyama

Tomonori Iida

Michinori Matsumoto

Taro Sakamoto

Ryusuke Ito

Takeshi Gocho

Kenei Furukawa

Yuki Fujiwara

Shoichi Hirohara

Takeyuki Misawa

Katsuhiko Yanaga

Affiliations

Soon will be listed here.

Abstract

Background: In perioperative management of hepatic resection for hepatocellular carcinoma, excessive blood loss and blood transfusion greatly influence postoperative complications and prognosis of the patients. We evaluated the influence of blood products use on postoperative recurrence and prognosis of patients with hepatocellular carcinoma.

Methods: The subjects were 66 patients who underwent elective hepatic resection for hepatocellular carcinoma without concomitant microwave or radiofrequency ablation therapy nor other malignancies between January 2001 and June 2006. We retrospectively investigated the influence of the use of blood products including red cell concentration and fresh frozen plasma on recurrence of hepatocellular carcinoma and overall survival.

Results: In multivariate analysis, the dose of blood products transfusion was a significant predictor of disease-free and overall survival. Both disease-free and overall survival rates of those who were given blood products were significantly worse than those who did not receive. On the other hand, in univariate analysis of disease-free and overall survival after hepatic resection and clinical variables, the amount of blood loss was not a significant predictor of recurrence or death.

Conclusion: Transfusion of blood products is associated with increased recurrence rate and worse survival after elective hepatic resection for patients with hepatocellular carcinoma.

Citing Articles

Imaoka Y, Ohira M, Imaoka K, Bekki T, Nakano R, Kuroda S BMC Surg. 2023; 23(1):86.

PMID: 37041491 PMC: 10091651. DOI: 10.1186/s12893-023-01986-9.

Impact of perioperative blood transfusion on long-term survival in patients with different stages of perihilar cholangiocarcinoma treated with curative resection: .

Liu Z, Cheng Z, Dai H, Zhong S, Zhao D, Gong Y Front Oncol. 2022; 12:1059581.

PMID: 36387093 PMC: 9660252. DOI: 10.3389/fonc.2022.1059581.

Impact of perioperative blood transfusions on postoperative renal function and survival after resection of colorectal liver metastases.

Rodieck W, Hallensleben M, Robert J, Beetz O, Grannas G, Cammann S World J Surg Oncol. 2022; 20(1):100.

PMID: 35354485 PMC: 8966349. DOI: 10.1186/s12957-022-02559-5.

Outcomes and recurrence patterns following curative hepatectomy for hepatocellular carcinoma patients with different China liver cancer staging.

Li C, Wang H, Chen R, Zhang H, Xu Y, Zhang B Am J Cancer Res. 2022; 12(2):907-921.

PMID: 35261811 PMC: 8899998.

Extracellular ubiquitin inhibits the apoptosis of hepatoma cells via the involvement of macrophages.

Cai J, Qian X, Qi Q, Han J, Zhu X, Zhang Q Transl Cancer Res. 2022; 9(4):2855-2864.

PMID: 35117642 PMC: 8798512. DOI: 10.21037/tcr.2020.03.12.

References

Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G . Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol. 2000; 12(2):195-203. DOI: 10.1093/intimm/12.2.195. View

Tralhao J, Kayal S, Dagher I, Sanhueza M, Vons C, Franco D . Resection of hepatocellular carcinoma: the effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients. Hepatogastroenterology. 2007; 54(76):1200-6. View

Fong Y, Sun R, Jarnagin W, Blumgart L . An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999; 229(6):790-9; discussion 799-800. PMC: 1420825. DOI: 10.1097/00000658-199906000-00005. View

Yamanaka N, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T . Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer. 1990; 65(5):1104-10. DOI: 10.1002/1097-0142(19900301)65:5<1104::aid-cncr2820650511>3.0.co;2-g. View

Tartter P, Burrows L, Kirschner P . Perioperative blood transfusion adversely affects prognosis after resection of Stage I (subset N0) non-oat cell lung cancer. J Thorac Cardiovasc Surg. 1984; 88(5 Pt 1):659-62. View

Blajchman M, Bordin J . Mechanisms of transfusion-associated immunosuppression. Curr Opin Hematol. 1994; 1(6):457-61. View

Brunson M, Alexander J . Mechanisms of transfusion-induced immunosuppression. Transfusion. 1990; 30(7):651-8. DOI: 10.1046/j.1537-2995.1990.30790385527.x. View

Krensky A, Clayberger C . Structure of HLA molecules and immunosuppressive effects of HLA derived peptides. Int Rev Immunol. 1996; 13(3):173-85. DOI: 10.3109/08830189609061746. View

Vamvakas E, Carven J . Exposure to allogeneic plasma and risk of postoperative pneumonia and/or wound infection in coronary artery bypass graft surgery. Transfusion. 2002; 42(1):107-13. DOI: 10.1046/j.1537-2995.2002.00001.x. View

10.

Blajchman M . Immunomodulation and blood transfusion. Am J Ther. 2002; 9(5):389-95. DOI: 10.1097/00045391-200209000-00005. View

11.

Fan S, Lo C, Liu C, Lam C, Yuen W, Yeung C . Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999; 229(3):322-30. PMC: 1191696. DOI: 10.1097/00000658-199903000-00004. View

12.

Yamasaki H, Okamoto E, Komatsu T, Manabe Y, Shinka S . Relationship between general or specific immunoreactivity and prognosis in postoperative patients with hepatocellular carcinoma. Cancer Immunol Immunother. 1990; 31(2):107-14. PMC: 11038566. DOI: 10.1007/BF01742374. View

13.

Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T . Postoperative recurrence of hepatocellular carcinoma. Ann Surg. 1990; 211(1):28-33. PMC: 1357889. DOI: 10.1097/00000658-199001000-00005. View

14.

Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T . Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology. 1993; 105(2):488-94. DOI: 10.1016/0016-5085(93)90724-q. View

15.

Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M . Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res. 2002; 24(4):395-403. DOI: 10.1016/s1386-6346(02)00144-4. View

16.

Belghiti J, Panis Y, Farges O, Benhamou J, Fekete F . Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991; 214(2):114-7. PMC: 1358509. DOI: 10.1097/00000658-199108000-00004. View

17.

Keller S, Groshen S, Martini N, Kaiser L . Blood transfusion and lung cancer recurrence. Cancer. 1988; 62(3):606-10. DOI: 10.1002/1097-0142(19880801)62:3<606::aid-cncr2820620327>3.0.co;2-q. View

18.

Tartter P . The association of perioperative blood transfusion with colorectal cancer recurrence. Ann Surg. 1992; 216(6):633-8. PMC: 1242709. DOI: 10.1097/00000658-199212000-00004. View

19.

Asahara T, Katayama K, Itamoto T, Yano M, Hino H, Okamoto Y . Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J Surg. 1999; 23(7):676-80. DOI: 10.1007/pl00012367. View

20.

Younes R, Rogatko A, Brennan M . The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases. Ann Surg. 1991; 214(2):107-13. PMC: 1358508. DOI: 10.1097/00000658-199108000-00003. View